ArticleJournal of translational medicine2025
Overexpression of oncogenic polo-like kinase 1 disrupts the invasiveness, cell cycle, and apoptosis in synovial sarcoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer.International journal of molecular sciences · 2026Article
- Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC.Journal of nanobiotechnology · 2026Article
- MicroRNA-29b-5p regulates cell proliferation and cancer stemness via TGF-β/p300 pathway in human synovial sarcoma.Cancer cell international · 2026Article
- FSCN1 drives sarcoma progression and immunosuppression revealed by pan-cancer analysis and functional assays.Discover oncology · 2026Article
- Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSynovial sarcoma (SS) is an aggressive malignant soft tissue sarcoma of undetermined tissue origin that harbors potential metastases and recurrences, leading to a poor prognosis. Polo-like kinase 1 (PLK1) is an essential member of the serine/threonine kinase family, which plays a key role in cell cycle progression and other cellular processes. Therefore, PLK1 could act as a promising target for treating various cancers, including a low incidence of sarcoma.
methodsSS paraffin-embedded tissue samples were selected to detect the expression of PLK1 and apoptosis- and autophagy-related proteins using immunohistochemistry. We analyzed the effects of low PLK1 expression on the SS cell cycle and function using the PLK1 inhibitor BI2536 in SW982 and SSX1 cells (cells with high expression of the SYT-SSX1 fusion gene). Western blotting was used to detect the expression of PLK1 and apoptotic proteins in different groups. Finally, the antitumor effects and safety of BI2536 were evaluated using xenograft tumor experiments in nude mice.
resultsIn SS tissues, PLK1 was overexpressed and autophagy-related proteins were expressed at low levels, leading to poor prognosis. Suppressing PLK1 expression using the PLK1 inhibitor BI2536 decreased the proliferation, migration, and invasion abilities of SW982 and SYT-SSX1 cells and promoted the expression of the apoptotic protein Bax. Meanwhile, we confirmed that SS cell apoptosis increased and G2/M cycle arrest occurred after PLK1 expression was inhibited. We found that BI2536 significantly inhibited the growth of SS-xenografted tumors in nude mice, and the expression of stem cell-related factors significantly decreased.
conclusionPLK1 overexpression was closely associated with poor prognosis. Suppressing PLK1 expression significantly inhibited the growth, invasion, and migration of SS cells, promoted apoptosis, and blocked the G2/M phase of the cell cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.